Get the Stockscreener App
0.50
5.26%
0.025
After Hours:
.47
-0.03
-6.00%
Silexion Therapeutics Corp stock is traded at $0.50, with a volume of 2.62M.
It is up +5.26% in the last 24 hours and down -48.72% over the past month.
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
See More
Previous Close:
$0.475
Open:
$0.4303
24h Volume:
2.62M
Relative Volume:
0.50
Market Cap:
$2.09M
Revenue:
-
Net Income/Loss:
$-11.91M
P/E Ratio:
-0.0564
EPS:
-8.8661
Net Cash Flow:
$-10.83M
1W Performance:
+73.01%
1M Performance:
-48.72%
6M Performance:
-77.38%
1Y Performance:
-96.62%
1-Day Range:
$0.4263
$0.51
1-Week Range:
$0.26
$0.666
52-Week Range:
$0.231
$22.36
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Name
Silexion Therapeutics Corp
Sector
Industry
Phone
972-8-6286005
Address
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
0.50 | 1.99M | 0 | -11.91M | -10.83M | -8.8661 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Silexion Therapeutics Corp Stock (SLXN) Latest News
Silexion Therapeutics (SLXN) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionAI Expert Picks - Newser
Silexion Therapeutics (SLXN): Modest Gains as Stock Holds Key Support at $0.46Percent Above MA - Newser
Silexion Therapeutics prices new warrants exercise deal at $0.50 to raise $1M - MSN
Silexion Therapeutics Stock Surges 97% on Phase 2/3 Trial Approval - Meyka
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN - TechStock²
Silexion Therapeutics(SLXN) Stock Options Chain | Quotes & News - Moomoo
Biotech Stock Silexion Therapeutics Corp. (NASDAQ: SLXN) Soars on Update and First Quarter Results - Investorideas.com
Silexion Therapeutics (SLXN) spikes as investors react to mid-May clinical-trial milestones and fresh financing - Quiver Quantitative
Silexion’s Cancer Trial Push Puts Focus on Cash - TechStock²
Silexion Therapeutics Posts Wider Q1 Loss, Advances SIL204 Into Phase 2/3 Trials; Stock Up - RTTNews
Silexion Therapeutics (SLXN) Gained +56.13% — Can It Break $0.44? 2026-05-20Volatility Smile - Newser
Silexion (NASDAQ: SLXN) 10-K amendment corrects internal control date - Stock Titan
Silexion Therapeutics (SLXN) Q1 2026 Earnings Surprise: EPS $-0.85, Up SignificantEarnings Beat Alert - Newser
Silexion Therapeutics 1Q Research and Development Approximately $1.4M >SLXN - Moomoo
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - Sahm
Silexion Therapeutics (SLXN) Declines -5.54% Amid Market Weakness 2026-05-18{涓偂鍓爣棰榼 - Newser
Silexion Therapeutics (SLXN) Stock: Down -5.54%, Support Test at $0.26 2026-05-18{涓偂鍓爣棰榼 - Newser
Silexion Shares Decline After Update on German Regulatory Review - MSN
Silexion reports Q1 results, advances SIL204 clinical path - grafa.com
Silexion Therapeutics Reports Q1 2026 Financial Results and Submits Phase 2/3 Clinical Trial Application for Pancreatic Cancer in Germany - Minichart
Silexion Therapeutics reports Q1 2026 net loss $2.7M, cash $2.4M; SIL204 Phase 2/3 approval - TradingView
Pancreatic cancer RNAi trial moves ahead as Silexion ramps up spending - Stock Titan
Silexion (NASDAQ: SLXN) Q1 loss widens as SIL204 moves into Phase 2/3 - Stock Titan
TradingKey - TradingKey
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds - Sahm
Silexion (SLXNW) Drops -22.58% — Key Support at $0.01 2026-05-15Earnings Miss Stocks - newser.com
Silexion Therapeutics Announces Warrant Inducement Financing Agreement - TipRanks
Silexion Therapeutics Corp 1Q 2026: Net loss $2.7M, EPS ($0.85) — 10-Q Summary - TradingView
Silexion Therapeutics (NASDAQ: SLXN) posts higher Q1 loss and flags going concern risk - Stock Titan
Silexion Therapeutics Corp Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Warrant deal gives Silexion (NASDAQ: SLXN) $1.0M cash and new overhang - Stock Titan
Lind Global files 13G/A: 212,500 warrants in Silexion (SLXN) - Stock Titan
Silexion raises $1M through warrant exercise at $0.50/share - Investing.com
Cancer biotech Silexion swaps warrant deal for $1M in new funding - Stock Titan
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer - Sahm
Silexion Announces Positive Preclinical Data for SIL204 Therapy - TipRanks
Silexion reports preclinical data on SIL204 in pancreatic cancer By Investing.com - Investing.com India
Silexion (SLXN) reports immune-related SIL204 signal in KRAS pancreatic cancer - Stock Titan
SLXNSilexion Therapeutics Corp stock news, filings & ratings - Quantisnow
Silexion Therapeutics reports positive preliminary immunotherapy findings for SIL204 in KRAS-driven pancreatic cancer - marketscreener.com
Silexion reports preclinical data on SIL204 in pancreatic cancer - Investing.com
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings For Sil204 In Kras-Driven Pancreatic Cancer - TradingView
Silexion Therapeutics Reports Positive Preclinical Results for SIL204 in KRAS-Mutated Pancreatic Cancer Study - Quiver Quantitative
Silexion Therapeutics Reports Positive Preliminary - GlobeNewswire
Silexion Therapeutics initiates GMP clinical batch manufacturing of SIL204 - TipRanks
Silexion starts GMP manufacturing of SIL204 and gets Phase 2/3 trial approval for pancreatic cancer. - Pluang
Silexion Therapeutics Announces GMP Clinical Supply Manufacturing Initiation for SIL204 and New Approval – SEC 8-K Filing May 2026 - Minichart
Silexion Advances SIL204 With Manufacturing and Trial Approval - TipRanks
Silexion (NASDAQ: SLXN) advances SIL204 with GMP batches and Phase 2/3 ethics approval - Stock Titan
Silexion begins clinical manufacturing of SIL204 for phase 2/3 trial By Investing.com - Investing.com South Africa
Silexion begins clinical manufacturing of SIL204 for phase 2/3 trial - Investing.com
Silexion Therapeutics Corp Stock (SLXN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):